marketcaparena
Search

    GENB

    Generate Biomedicines, Inc.

    Company overview

    Market capitalization
    $1.91B
    Employees
    312
    Latest publication
    2026-09-29
    About Generate Biomedicines, Inc.

    Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

    Company website

    Financial statements

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USD
    Total Assets625,737,000USD
    Other Current Assets18,749,000USD
    Total Liab110,936,000USD
    Total Stockholder Equity514,801,000USD
    Other Current Liab19,267,000USD
    Common Stock128,000USD
    Capital Stock128,000USD
    Retained Earnings-737,739,000USD
    Cash160,575,000USD
    Cash And Short Term Investments516,640,999USD
    Total Current Assets535,390,000USD
    Total Current Liabilities58,389,000USD
    Current Deferred Revenue17,244,000USD
    Net Debt-95,005,000USD
    Short Term Debt14,261,000USD
    Short Long Term Debt Total65,570,000USD
    Short Term Investments356,066,000USD
    Accounts Payable7,617,000USD
    Property Plant Equipment Net85,602,000USD
    Property Plant Equipment Gross137,132,000USD
    Accumulated Other Comprehensive Income24,000USD
    Common Stock Shares Outstanding128,192,484shares
    Non Current Assets Total90,346,999USD
    Non Current Liabilities Total52,547,000USD
    Non Currrent Assets Other4,744,999USD
    Net Working Capital477,001,000USD
    Unclassified Non Current Liabilities52,547,000USD
    Unclassified Equity1,252,260,000USD
    SourceLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Total Assets330,182,000USD518,259,000USD
    Other Current Assets12,867,000USD13,556,000USD
    Total Liab953,379,000USD953,349,000USD
    Total Stockholder Equity-615,965,000USD-434,519,000USD
    Other Current Liab42,164,000USD21,817,000USD
    Common Stock50,000USD50,000USD
    Capital Stock33,000USD33,000USD
    Retained Earnings-676,293,000USD-473,139,000USD
    Cash121,650,000USD176,269,000USD
    Cash And Short Term Investments221,498,000USD393,627,000USD
    Total Current Assets234,365,000USD407,491,000USD
    Total Current Liabilities82,203,000USD86,626,000USD
    Current Deferred Revenue21,194,000USD42,425,000USD
    Net Debt-53,124,000USD-99,297,000USD
    Short Term Debt15,008,000USD16,717,000USD
    Short Long Term Debt Total68,526,000USD76,972,000USD
    Short Term Investments99,848,000USD217,358,000USD
    Net Receivables0USD308,000USD
    Accounts Payable3,837,000USD5,667,000USD
    Property Plant Equipment Net89,011,000USD101,068,000USD
    Property Plant Equipment Gross137,268,000USD136,240,000USD
    Accumulated Other Comprehensive Income106,000USD118,000USD
    Common Stock Shares Outstanding50,088,504shares127,450,201shares
    Non Current Assets Total95,817,000USD110,768,000USD
    Non Current Liabilities Total871,176,000USD866,723,000USD
    Non Current Liabilities Other116,000USD349,000USD
    Non Currrent Assets Other6,806,000USD9,700,000USD
    Net Working Capital152,162,000USD320,865,000USD
    Unclassified Non Current Liabilities871,060,000USD866,374,000USD
    Unclassified Equity60,139,000USD38,419,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ1 20252025-03-31 · USD
    Net Income-61,446,000USD-41,685,000USD
    Depreciation3,273,000USD3,414,000USD
    Stock Based Compensation6,395,000USD4,744,000USD
    Other Non Cash Items8,438,000USD1,339,000USD
    Change To Account Receivables0USD-91,000USD
    Change In Working Capital-30,653,000USD-17,440,000USD
    Total Cash From Operating Activities-80,388,000USD-53,176,000USD
    Capital Expenditures-3,781,000USD-751,000USD
    Free Cash Flow-84,169,000USD-53,927,000USD
    Investments-256,153,000USD76,283,000USD
    Total Cashflows From Investing Activities-252,434,000USD—
    Net Borrowings-1,115,000USD-2,646,000USD
    Total Cash From Financing Activities371,391,000USD20,560,000USD
    Issuance Of Capital Stock369,289,000USD21,973,000USD
    Change In Cash160,575,000USD42,916,000USD
    Begin Period Cash Flow126,038,000USD181,831,000USD
    End Period Cash Flow160,575,000USD224,747,000USD
    Unclassified Operating Cash Flow-6,395,000USD-3,548,000USD
    Unclassified Investing Cash Flow7,500,000USD—
    Unclassified Financing Cash Flow—1,233,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Net Income-222,965,000USD-181,384,000USD
    Depreciation13,178,000USD15,349,000USD
    Stock Based Compensation20,577,000USD19,465,000USD
    Other Non Cash Items3,207,000USD702,000USD
    Change To Account Receivables308,000USD-213,000USD
    Change In Working Capital-14,616,000USD28,118,000USD
    Total Cash From Operating Activities-200,619,000USD-117,750,000USD
    Capital Expenditures-3,514,000USD-3,447,000USD
    Free Cash Flow-204,133,000USD-121,197,000USD
    Investments120,281,000USD-54,288,000USD
    Total Cashflows From Investing Activities116,767,000USD-57,725,000USD
    Net Borrowings-8,161,000USD-11,124,000USD
    Total Cash From Financing Activities28,059,000USD91,327,000USD
    Issuance Of Capital Stock21,973,000USD96,324,000USD
    Change In Cash-55,793,000USD-84,148,000USD
    Begin Period Cash Flow181,831,000USD265,979,000USD
    End Period Cash Flow126,038,000USD181,831,000USD
    Other Cashflows From Financing Activities36,220,000USD102,451,000USD
    Unclassified Financing Cash Flow-21,973,000USD-96,324,000USD
    Other Cashflows From Investing Activities—10,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    No revenue breakdown is currently published for this company.

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.